Neuroimaging Predictors of Relapse During Treatment for Opiate Dependence

Overview

This study proposes to use functional magnetic resonance imaging (FMRI) to observe brain activity and behavior associated with decision-making about rewards (DD task), working memory and working memory cognitive persistence (WM task), and craving (CR task) in 72 opiate dependent participants initiating buprenorphine. While stably using opiates (initial study appointment) and again during withdrawal (approximately 3 days later), participants will receive an FMRI scan with behavioral challenges; immediately after the second FMRI, they will receive their first dose of buprenorphine. Buprenorphine treatment will continue for twelve weeks, followed by a four week taper. Urine toxicological analysis will be performed prior to the first scanning session, weekly for two weeks and biweekly thereafter. Participation for all individuals will last 4 months. Assessments will occur at baseline, and weeks 1, 2, 4, 8, and 12. Buprenorphine induction will begin at the completion of the second scan; follow-up medical visits will align with study assessments on weeks 1, 2, 4, 8 and 12. All participants will receive 16 weeks of buprenorphine (the final 4 of these 16 weeks will include a taper).

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Other
    • Masking: None (Open Label)
  • Study Primary Completion Date: February 2020

Interventions

  • Other: FMRI
    • all participants will complete 2 FMRIs
  • Drug: Suboxone
    • all participants will be prescribed Suboxone for 4 months during their study participation

Arms, Groups and Cohorts

  • Other: All Participants
    • FMRI Suboxone

Clinical Trial Outcome Measures

Primary Measures

  • Changes in Resting State Disorganization Between Baseline and One Week by Person by Lapsed Category
    • Time Frame: Baseline and 1 week
    • The measure of resting state organization is a z-value derived from Pearson’s r-values. They represent the effect of the association between the brain activity of the seed region and each brain voxel over time during the resting state FMRI scan. A central z-value of 0 means that there is no association between the seed region and the voxel. Positive and negative z-values approaching 0 reflect increasingly weaker associations, and more extreme positive and negative values reflect stronger associations. Attributing the qualitative labels better or worse to these values depend upon the brain network and context. In many networks (eg, task-positive cognitive control network), a stronger positive correlation is thought to reflect better network organization. In the task-negative default mode network a stronger positive relationship is considered by some as worse. For this study, these are not yet used as clinical measures and there are not known cutoffs.
  • Working Memory – Between Groups at Baseline by Lapsed Category
    • Time Frame: Baseline
    • fMRI working memory differences between participants who lapse back to opioid use and those who don’t
  • Changes in Working Memory – Within Groups During Satiation and Withdrawal
    • Time Frame: Baseline and 1 week
    • fMRI working memory differences under satiation vs withdrawal from opioids

Participating in This Clinical Trial

Inclusion Criteria

  • opiate dependent persons – 21-50 years old – interested in initiating outpatient buprenorphine treatment Exclusion Criteria:

  • current methadone maintenance treatment program participation – medically necessary prescription opiate treatment (e.g., for chronic pain) – current criteria for a DSM-V diagnosis of substance dependence for sedative or hypnotic drugs, alcohol, stimulants, cocaine, inhalants, hallucinogens – diagnosis of organic brain disorder, bipolar disorder, schizophrenia, schizo-affective, schizophreniform or paranoid disorder – current suicidality on the Modified Scale for Suicidal Ideation – evidence of neuropsychological dysfunction as assessed by the study physician with confirmation with the Folstein Mini-Mental Status Examination• – anticipated major painful event (significant surgical procedure) in the coming 4 months – probation or parole requirements or an upcoming move that might interfere with protocol participation – history of allergic reaction to buprenorphine or naloxone – currently pregnant or planning to become pregnant in the next 4 months – history of neurological disorder (e.g., epilepsy, stroke, brain injury) – impaired uncorrected vision – FMRI contraindications (e.g., claustrophobia, specific metallic implants and injuries)

Gender Eligibility: All

Minimum Age: 21 Years

Maximum Age: 50 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Butler Hospital
  • Provider of Information About this Clinical Study
    • Principal Investigator: Michael Stein, MD, Principle Investigator – Butler Hospital

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.